Three dimensional conformal radiotherapy / intensity modulated radiotherapy alone vs three dimensional conformal therapy / intensity modulated radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Ropidoxuridine
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 26 Jul 2021 Primary endpoint has not been met (Overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided = 5%) , according to Results published in the Journal of Clinical Oncology
- 26 Jul 2021 Primary endpoint has been met (DFS by intention-to-treat stratified by EBRT dose at two-sided = 5%) , according to Results published in the Journal of Clinical Oncology
- 26 Jul 2021 Primary endpoint has been met (EFS by intention-to-treat stratified by EBRT dose at two-sided = 5%) , according to Results published in the Journal of Clinical Oncology